Publicaciones en las que colabora con María de Ujue Moreno Zulategui (45)

2024

  1. Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial

    Hypertension Research

2023

  1. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides

    JACC: Heart Failure, Vol. 11, Núm. 1, pp. 58-72

2022

  1. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

2021

  1. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

2020

  1. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

    Nefrologia, Vol. 40, Núm. 3, pp. 223-236

2019

  1. Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study

    Journal of Cardiovascular Electrophysiology, Vol. 30, Núm. 8, pp. 1231-1240

  2. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation: Mechanistic insights and clinical implications

    Hypertension, Vol. 73, Núm. 3, pp. 602-611

  3. Circulating long noncoding RNA LIPCAR Predicts heart failure outcomes in patients without chronic kidney disease

    Hypertension, Vol. 73, Núm. 4, pp. 820-828

  4. Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation

    Journal of the American College of Cardiology, Vol. 73, Núm. 12, pp. 1398-1410

  5. The renal immune-inflammatory component of arterial hypertension: Emerging therapeutic strategies

    Cardiovascular Research, Vol. 115, Núm. 4, pp. 696-698

2018

  1. Myocardial remodeling in hypertension toward a new view of hypertensive heart disease

    Hypertension, Vol. 72, Núm. 3, pp. 549-558

2017

  1. Hypertensive Heart Disease

    Encyclopedia of Cardiovascular Research and Medicine (Elsevier), pp. 517-526

  2. Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men

    Free Radical Research, Vol. 51, Núm. 4, pp. 389-396

  3. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites

    Scientific Reports, Vol. 7

  4. Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome

    Journal of Hypertension, Vol. 35, Núm. 4, pp. 853-861

  5. The Hypertensive Myocardium: From Microscopic Lesions to Clinical Complications and Outcomes

    Medical Clinics of North America, Vol. 101, Núm. 1, pp. 43-52

2016

  1. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure

    Journal of the American College of Cardiology, Vol. 67, Núm. 3, pp. 251-260

  2. Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients

    Clinical Science, Vol. 130, Núm. 23, pp. 2139-2149

2015

  1. Circulating biomarkers of myocardial fibrosis: The need for a reappraisal

    Journal of the American College of Cardiology, Vol. 65, Núm. 22, pp. 2449-2456

2014

  1. Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease: A Role for Cardiotrophin-1?

    Hypertension, Vol. 63, Núm. 3, pp. 468-474